
|Videos|January 15, 2014
Treating NSCLC With Nintedanib
Author(s)Chandra P. Belani, MD
Chandra P. Belani, MD, discusses the VEGF-targeted agent nintedanib (BIBF 1120).
Advertisement
Chandra P. Belani, MD, Deputy Director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses the VEGF-targeted agent nintedanib (BIBF 1120).
Clinical Pearls:
- Nintedanib was studied in combination with docetaxel in a phase III randomized study of NSCLC
- This study showed an improvement in progression-free survival
- In a second trial, in combination with pemetrexed, nintedanib showed no benefit to progression-free survival
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
3
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5




























